Blended Solutions
Bespoke, seamless solutions to meet unique sponsor challenges.
Whitepaper: Embracing a blended operating model
Outsourcing encompasses more than half the total global clinical development spend. As a result, the way the industry outsources is evolving to maximise ROI and efficiency amid increasing complexity and difficulty within the clinical development landscape.
Whitepaper: How investments in supply of CRAs is better than competing with the demand for CRAs
In this whitepaper, ICON’s experts address our commitment to four main objectives to reducing the CRA drought.
Whitepaper: The evolution of FSP, not just for large pharma
For mid-size pharma, CRO and FSP models may evolve as the company grows. This either/or decision often means switching models by switching suppliers. By harnessing the ‘Embedded Blended’ model, all sponsors can benefit from a synchronised outsourcing strategy.
Whitepaper: Clinical trials in Japan: An enterprise growth and management strategy
Presenting a unique approach to evolve the traditional local clinical development model in Japan, while lowering costs, improving productivity, and potentially accelerating drug approval timelines.
Media contributions
-
Media article: Blended outsourcing models: Driving strategic flexibility and operational excellence
The clinical research industry is at a turning point. As trials grow more complex and development costs continue to rise, biopharma sponsors are reevaluating how they partner more efficiently with CROs.
-
Media article: Curated and customised outsourcing
As the outsourcing market evolves, pharmaceutical businesses are reassessing their strategies to better insulate themselves against the pressure of compounding macroeconomic constraints, including a looming patent cliff, rising costs and developmental risks.
-
Media article: Blending Models for Better Sourcing Solutions
There is a growing trend among large and midsize pharma in turning toward more strategic partnerships to help them navigate the increasing complexity of the development landscape and the compounding macroeconomic constraints.
-
Media article: Evolution in the outsourcing of clinical research
Partnership is an increasingly important criterium for bio/pharmaceutical sponsors as they seek more bespoke solutions and the flexibility of tailored outsourcing models.
-
Media article: Redefining CRO sourcing model terminology to optimise outsourcing strategies
Samir Shah, President, Strategic Solutions at ICON contributes to this Applied Clinical Trials article discussing the compelling need for new terminology for sourcing models in the CRO industry.
-
Media article: A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid-size pharmaceutical and biotech companies.
-
Media article: Embedded blended solutions - A new way to optimise clinical trial portfolio delivery
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.
-
Media article: A golden opportunity… but not a silver bullet
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked.
Blogs
-
Blog: Best practices for KPI management in FSP partnerships
Learn more about the best practices for KPI creation and management in this blog.
-
Blog: Redefining sourcing model terminology
As clinical development services and outsourcing models have become more complex, we have outgrown old definitions these models. This blog explores the new framework for defining CRO sourcing models and explains its importance.
-
Blog: How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
-
Blog: Global Outsourcing Strategies
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
Blended Solutions
ICON provides blended solutions with custom configurations to address sponsor challenges through seamlessly integrated service delivery. ICON combines world-leading global FSP solutions, FSO, standalone, and specialty services for efficiency and control. Expert consultants guide transitions and use formal governance to optimize the benefits of a bespoke, flexible, and efficient model.
Explore our library of case studies to find out how we have increased operating efficiencies for our clients.